Skip to main content
Journal of Clinical Oncology logoLink to Journal of Clinical Oncology
. 2019 Feb 1;37(4):354. doi: 10.1200/JCO.18.02212

Errata

PMCID: PMC6827956  PMID: 30695655

The February 10, 2016, article by Hortobagyi et al entitled “Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2” (J Clin Oncol 34:419-426, 2016) was published online October 26, 2015, with errors in the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Baselga’s COIs were given as:

José Baselga

Honoraria: Novartis, Infinity

Consulting or Advisory Role: Novartis, Verastem, Infinity

They should have read as:

José Baselga

Leadership: Infinity Pharmaceuticals, Aura Biosciences

Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Aura Biomedical, Apogen, Seragon, Aragon, Verastem

Honoraria: Infinity Pharmaceuticals, PMV Pharma, Juno Therapeutics, GRAIL, Seragon

Consulting or Advisory Role: Novartis, Eli Lilly, GRAIL, AstraZeneca

Research Funding: Roche/Genentech

Travel, Accommodations, Expenses: Roche/Genentech

This has been corrected as of January 11, 2019. The author apologizes for the errors.


Articles from Journal of Clinical Oncology are provided here courtesy of American Society of Clinical Oncology

RESOURCES